Drugmaker GSK said on Monday that its relapsed or refractory multiple myeloma drug candidate, Blenrep, had failed to meet its primary endpoint of progression-free survival in a recent phase III trial.
GSK stated the main goal of its late-stage DREAMM-3 study was to show that the treatment was superior to the standard of care currently on the market. However, Blenrep failed to do so.
Data from the trial will be shared with health authorities and discussions had commenced, with additional trials of Blenrep set to continue as previously planned.
Blenrep was granted accelerated approval by the Food and Drug Administration as a monotherapy for treating adult patients with RRMM who have received at least four prior therapies. The accelerated approval was based on the results of its DREAMM-2 overall response rate.
As of 0830 GMT, GSK shares were down 2.74% at 1,406.0p.
Reporting by Iain Gilbert at Sharecast.com
